A recent observational study was performed on 122 persons with type 2 diabetes, 61 were treated with oral hypoglycaemic agents alone, and 61 were treated with a combination of oral hypoglycaemic agents and insulin at either a low dose (<0.40 unit/kg/day) or high dose (≥0.40 unit/kg/day). The gene discussed is INS; the disease is type 2 diabetes mellitus.